[PDF][PDF] The role of the fallopian tube in ovarian cancer

AA Tone, S Salvador, SJ Finlayson… - Clin Adv Hematol …, 2012 - researchgate.net
High-grade serous carcinoma (HGSC) is the most common and lethal subtype of ovarian
cancer. Research over the past decade has strongly suggested that “ovarian” HGSC arises …

[HTML][HTML] Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary

SP Shah, M Köbel, J Senz, RD Morin… - … England Journal of …, 2009 - Mass Medical Soc
Background Granulosa-cell tumors (GCTs) are the most common type of malignant ovarian
sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover …

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

EA Eisenhauer, WW ten Bokkel Huinink… - Journal of clinical …, 1994 - ascopubs.org
PURPOSE Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer
agent with activity in a number of human tumors, including epithelial ovarian cancer. In …

Differences in tumor type in low-stage versus high-stage ovarian carcinomas

M Köbel, SE Kalloger, DG Huntsman… - International Journal …, 2010 - journals.lww.com
Although there are recognized differences in the type of ovarian carcinomas between those
tumors diagnosed at low versus high stage, there is a lack of data on stage distribution of …

Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention

JN McAlpine, GE Hanley, MMM Woo, AA Tone… - American journal of …, 2014 - Elsevier
Objective The purpose of this study was to assess the uptake and perioperative safety of
bilateral salpingectomy (BS) as an ovarian cancer risk-reduction strategy in low-risk women …

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

PJ Hoskins, KD Swenerton, JA Pike, F Wong… - Journal of Clinical …, 2001 - ascopubs.org
PURPOSE: To evaluate the efficacy of carboplatin plus paclitaxel in primarily advanced or
recurrent endometrial cancers. PATIENTS AND METHODS: Four distinct patient groups …

Prognostic factors in metastatic breast cancer treated with combination chemotherapy

KD Swenerton, SS Legha, T Smith, GN Hortobagyi… - Cancer Research, 1979 - AACR
Six hundred nineteen patients with metastatic breast cancer, treated with a combination of 5-
fluorouracil, Adriamycin, and cyclophosphamide, or close variations of this program, with or …

[HTML][HTML] HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

JN McAlpine, KC Wiegand, R Vang, BM Ronnett… - BMC cancer, 2009 - Springer
Background The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is
low, prompting interest in targeted molecular therapies. We investigated HER2 expression …

Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications

M Köbel, SE Kalloger, JL Santos, DG Huntsman… - Gynecologic …, 2010 - Elsevier
OBJECTIVE: An ability to predict survival is of crucial importance in determining the need for
cancer therapy. Recent advances in tumor typing of ovarian carcinomas lead to a …

[PDF][PDF] Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation

PJ Hoskins, N Le, B Gilks, A Tinker… - Journal of clinical …, 2012 - researchgate.net
Low-Stage Ovarian Clear Cell Carcinoma: Population-Based Outcomes in British Columbia,
Canada, With Evidence for a Survival Bene Page 1 Low-Stage Ovarian Clear Cell Carcinoma …